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Pharmacokinetic Implications of Intestinal P-glycoprotein 
in Diabetic Complications 
Abstract 
This study was designed with an objective to understand the effect of intestinal P-
glycoprotein on pharmacokinetic profile of its substrates (verapamil and atorvastatin) in 
diabetes with hyperlipidemia. Mechanistically, the change in intestinal P-glycoprotein 
expression and activity with progression of diabetes and its effect on intestinal uptake as 
well as pharmacokinetics of its substrates was evaluated. In this study, the mechanism of 
action of epigallocatechin-3-gallate (EGCG) which is reported as a potential P-glycoprotein 
inhibitor was also elucidated. Initially, the animal model for diabetes with hyperlipidemia 
was developed. This was followed by intestinal mucosal protein content analysis which 
inferred that total protein increased from duodenum towards the ileum and with the 
progression of diabetes. Thereafter, single pass intestinal perfusion study was performed in 
normal and diabetic rats. It was observed that effective permeability of P-glycoprotein 
substrates viz. verapamil and atorvastatin decreased from duodenum to ileum and also with 
progression of disease. Co-perfusion of EGCG with verapamil or atorvastatin significantly 
improved their intestinal uptake. Thereafter, pharmacokinetic studies were done in normal 
and diabetic rats to determine the presence of any change in the oral bioavailability of P-
glycoprotein substrates with the progression of disease. The oral bioavailability of P-
glycoprotein substrates decreased significantly with the progression of diabetes; however, 
co-administration of EGCG with P-glycoprotein substrates significantly improved their 
bioavailability in normal as well as in diabetic animals. In order to have a mechanistic 
insight, expression and activity of P-glycoprotein in intestinal segment of normal and 
diabetic animals were studied. The expression level of mdr1a and mdr1b genes that encoded 
for P-glycoprotein were determined by RT-PCR analysis whereas activity of P-glycoprotein 
was determined by quantifying the Na+-K+-ATPase enzyme activity in intestinal mucosal 
samples of normal and diabetic animals. It was observed that both expression and activity of 
P-glycoprotein was significantly higher in diabetic animals as compared to normal animals 
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and also increased with the progression of disease. It was also observed that intestinal 
oxidative stress and advanced glycation end-products (AGEs) levels, which are responsible 
for modulating expression of P-glycoprotein, was higher in diabetic animals as compared to 
normal. Treatment with EGCG significantly reduced the expression and activity of intestinal 
P-glycoprotein as well as intestinal oxidative stress and AGEs level in both normal and 
diabetic animals. It can be inferred from the obtained results that increased intestinal 
oxidative stress and AGEs level triggered the expression and activity of P-glycoprotein. 
This condition subsequently decreased the intestinal uptake and oral bioavailability of its 
substrates. Treatment with EGCG improved the intestinal uptake and oral bioavailability of 
P-glycoprotein substrates, by reducing the expression and activity of intestinal P-
glycoprotein as well as intestinal oxidative stress and AGEs level. This study gave a 
mechanistic insight about the bioenhancement potential of EGCG. Hence, monitoring the 
enhanced expression and activity of P-glycoprotein in diabetes will be helpful in effective 
therapeutic drug monitoring and EGCG may be opted as an adjuvant therapy for 
overcoming P-glycoprotein mediated drug efflux. 
 
